PeptiMatrix: Next generation peptide hydrogels for 3D cell culture

PeptiMatrix：用于 3D 细胞培养的下一代肽水凝胶

• 批准号: 10070302
• 金额: $ 34.49万
• 依托单位: PEPTIMATRIX
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10070302
• 关键词: PeptiMatrix; Next; generation; peptide; hydrogels

Current _in vitro_ models of development and disease typically fail to recapitulate the complexities of native tissue microenvironments, leading to a poor extrapolation of _in vitro_ findings to _in vivo_ relevance. This is a major contributing factor to the high attrition rate of new drugs moving from the lab to the clinic, leading to an estimated cost of US$2 billion to bring a new lifesaving therapy to market.Growing recognition of this has led to a recent interest in developing more sophisticated 3D _in vitro_ model platforms which allow for customisation of matrix stiffness and composition. However, despite considerable research effort, no single platform has yet pulled ahead of the competition. With the support of the BBSRC and NC3Rs, we have developed a fully synthetic self-assembling peptide hydrogel (SAPH) platform which aims to address all the current shortcomings of available 3D _in vitro_ model platforms.PeptiMatrix(tm) is chemically well-defined, has limited batch variability, and contains no irrelevant animal-derived material. It can also be customised via a variety of available methods to match the stiffness and composition of any target tissue type. Each formulation of PeptiMatrix(tm) will, therefore, have been specifically tailored to model a specific tissue or tissue type and validated in a relevant cell-based assay.PeptiMatrix(tm) is supplied ready-to-use: simply combine with your cells of interest and plate out. Your cells will then cluster and grow in 3D, in a physiologically relevant and reproducible way. This saves time versus similar products that require complex preparatory steps or require that you customise (and optimise) the hydrogel yourself.

目前的发育和疾病的体外模型通常无法概括天然组织微环境的复杂性，导致体外研究结果与体内相关性的外推效果不佳。这是导致新药从实验室转移到临床的高损耗率的一个主要因素，导致将一种新的救命疗法推向市场的估计成本为 20 亿美元。对此的日益认识引起了人们最近的兴趣开发更复杂的 3D 体外模型平台，该平台允许定制基质刚度和成分。然而，尽管进行了大量的研究工作，但还没有任何一个平台在竞争中处于领先地位。在 BBSRC 和 NC3Rs 的支持下，我们开发了一个全合成的自组装肽水凝胶 (SAPH) 平台，旨在解决当前可用 3D _体外_ 模型平台的所有缺点。PeptiMatrix(tm) 化学结构明确，批次变异性有限，并且不含不相关的动物源性材料。它还可以通过各种可用方法进行定制，以匹配任何目标组织类型的硬度和成分。因此，PeptiMatrix(tm) 的每种配方都经过专门定制，以模拟特定组织或组织类型，并在相关的基于细胞的测定中进行验证。PeptiMatrix(tm) 提供即用型：只需与您的细胞结合即可兴趣并盘出。然后，您的细胞将以生理相关且可重复的方式在 3D 中聚集和生长。与需要复杂准备步骤或需要您自己定制（和优化）水凝胶的类似产品相比，这可以节省时间。